Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 2 , Pages 145-149 , March 2012

Tumor cytoreduction results in better response to androgen ablation—a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer

  • Xiao-Jian Qin, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Chun-Guang Ma, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Ding-Wei Ye, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • Corresponding Author InformationCorresponding author. Tel.: +862164175590; fax: +862164175590
    • ,
  • Xu-Dong Yao, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Shi-Lin Zhang, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Bo Dai, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Hai-Liang Zhang, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Yi-Jun Shen, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Yao Zhu, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Yi-Ping Zhu, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Guo-Hai Shi, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Wen-Jun Xiao, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Guo-Wen Lin, M.D.

      Affiliations

    • Department of Urology, Fudan University Shanghai Cancer Centre, Shanghai, China
    • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
    • ,
  • Gregory P. Swanson, M.D.

      Affiliations

    • Department of Radiology and Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA

Received 2 November 2009 ,Revised 6 February 2010 ,Accepted 10 February 2010.

References 

  1. Crain DS , Amling CL , Kane CJ . Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer . J Urol . 2004;171:668–671
  2. Choueiri TK , Xie W , D'Amico AV , et al.  Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy . Cancer . 2009;115:981–987
  3. Heidenreich A , Aus G , Bolla M , et al.  EAU Guidelines on Prostate Cancer . Eur Urol . 2008;53:68–80
  4. Akaza H , Yamaguchi A , Matsuda T , et al.  Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist vs. LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: Interim results of a randomized study in Japanese patients . Jpn J Clin Oncol . 2004;34:20–28
  5. Klotz L , Schellhammer P , Carroll K . A reassessment of the role of combined androgen blockade for advanced prostate cancer . BJU Int . 2004;93:1177–1182
  6. Leibovici D , Pagliaro L , Rosser CJ , et al.  Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy . J Urol . 2005;173:781–783
  7. Leibovici D , Kamat AM , Pettaway CA , et al.  Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer . J Urol . 2005;174:2186–2190
  8. Hallissey MT , Allum WH , Roginski C , et al.  Palliative surgery for gastric cancer . Cancer . 1988;62:440–444
  9. Temple LK , Hsieh L , Wong WD , et al.  Use of surgery among elderly patients with stage IV colorectal cancer . J Clin Oncol . 2004;22:3475–3484
  10. Rapiti E , Verkooijen HM , Vlastos G , et al.  Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis . J Clin Oncol . 2006;24:2743–2749
  11. Flanigan RC , Salmon SE , Blumenstein BA , et al.  Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer . N Engl J Med . 2001;345:1655–1659
  12. Ward JF , Slezak JM , Blute ML , et al.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate specific antigen testing: 15-Year outcome . BJU Int . 2005;95:751–756
  13. Johnstone PA , Ward KC , Goodman M , et al.  Radical prostatectomy for clinical T4 prostate cancer . Cancer . 2006;106:2603–2609
  14. Ghavamian R , Bergstralh EJ , Blute ML , et al.  Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison . J Urol . 1999;161:1223–1227
  15. Swanson GP , Riggs M , Earle J . Failure after primary radiation or surgery for prostate cancer: Differences in response to androgen ablation . J Urol . 2004;172:525–528
  16. Thompson IM , Tangen C , Basler J , et al.  Impact of previous local treatment for prostate cancer on subsequent metastatic disease . J Urol . 2002;168:1008–1012
  17. Hussain M , Goldman B , Tangen C , et al.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 . J Clin Oncol . 2009;27:2450–2456
  18. Peyromaure M , Debre B , Mao K , et al.  Management of prostate cancer in China: A multicenter report of 6 institutions . J Urol . 2005;174:1794–1797
  19. Swanson G , Thompson I , Basler J , et al.  Metastatic prostate cancer—does treatment of the primary tumor matter? . J Urol . 2006;176:1292–1298
  20. Mostaghel EA , Page ST , Lin DW , et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer . Cancer Res . 2007;67:5033–5041

PII: S1078-1439(10)00051-7

doi: 10.1016/j.urolonc.2010.02.010

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 2 , Pages 145-149 , March 2012

Article Tools

* Image Usage & Resolution